Result Number | Material Type | Add to My Shelf Action | Record Details and Options |
---|---|---|---|
1 |
Material Type: Artigo
|
![]() |
Parathyroid hormone‐related protein measured at the time of first visit is an indicator of bone metastases and survival in lung carcinoma patients with hypercalcemiaHiraki, Akio ; Ueoka, Hiroshi ; Bessho, Akihiro ; Segawa, Yoshihiko ; Takigawa, Nagio ; Kiura, Katsuyuki ; Eguchi, Kenji ; Yoneda, Toshiyuki ; Tanimoto, Mitsune ; Harada, MineCancer, 2002-10, Vol.95 (8), p.1706-1713 [Periódico revisado por pares]New York: Wiley Subscription Services, Inc., A Wiley CompanyTexto completo disponível |
2 |
Material Type: Artigo
|
![]() |
Fragile histidine triad transcription abnormalities and human papillomavirus E6–E7 mRNA expression in the development of cervical carcinomaSegawa, Tomoya ; Sasagawa, Toshiyuki ; Yamazaki, Hiroshi ; Sakaike, Jun ; Ishikawa, Hiroshi ; Inoue, MasakiCancer, 1999-05, Vol.85 (9), p.2001-2010 [Periódico revisado por pares]New York: John Wiley & Sons, IncTexto completo disponível |
3 |
Material Type: Artigo
|
![]() |
A randomized trial of hybrid administration of cyclophosphamide, doxorubicin, and vincristine (CAV)/cisplatin and etoposide (PVP) versus sequential administration of CAV-PVP for the treatment of patients with small cell lung carcinoma results of long term follow-upUEOKA, H ; KIURA, K ; TABATA, M ; KAMEI, H ; GEMBA, K ; SAKAE, K ; HIRAKI, Y ; HIRAKI, S ; SEGAWA, Y ; HARADA, MCancer, 1998-07, Vol.83 (2), p.283-290 [Periódico revisado por pares]New York, NY: Wiley-LissTexto completo disponível |
4 |
Material Type: Artigo
|
![]() |
Pilot study of cyclophosphamide‐doxorubicin‐vincristine‐cisplatin‐etoposide hybrid chemotherapy in small cell lung cancerOhnoshi, Taisuke ; Hiraki, Shunkichi ; Ueoka, Hiroshi ; Kiura, Katsuyuki ; Kamei, Haruhito ; Horiguchi, Takashi ; Kodani, Tsuyoshi ; Maeda, Tadashi ; Tabata, Masahiro ; Shibayama, Takuo ; Segawa, Yoshihiko ; Miyatake, Kazuyo ; Takigawa, Nagio ; Kimura, IkuroCancer, 1993-09, Vol.72 (5), p.1597-1601 [Periódico revisado por pares]New York: Wiley Subscription Services, Inc., A Wiley CompanyTexto completo disponível |